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5LETTER TO THE EDITOR
e: Chronic Graft-versus-Host DiseaseR
1
2We realized recently that the regimen described
or the administration of calcineurin inhibitor for
reatment of chronic graft-versus-host disease (cGvHD)
n our previous article (BBMTApril 2003; 9(4): 215–233)
s discrepant from current practice. In the article we
rescribed an alternate-day calcineurin inhibitor regi-
en based on dosing in clinical trials [1,2]. However,
e wish readers to know that we currently administer
alcineurin inhibitor twice daily instead of the alter-
ate-day regimen for treatment of cGvHD. Although
esults for the two regimens have not been formally
ompared, the elimination of the taper to alternate-
ay dosing was based primarily on pharmacokinetics
onsiderations. We apologize for the error.
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